2213-08-3Relevant articles and documents
Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core
Dyck, Brian,Grigoriadis, Dimitri E.,Gross, Raymond S.,Guo, Zhiqiang,Haddach, Mustapha,Marinkovic, Dragan,McCarthy, James R.,Moorjani, Manisha,Regan, Collin F.,Saunders, John,Schwaebe, Michael K.,Szabo, Tomas,Williams, John P.,Zhang, Xiaohu,Bozigian, Haig,Chen, Ta Rung
, p. 4100 - 4110 (2005)
Two new classes of tricyclic-based corticotropin-releasing factor (CRF 1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
-
Page/Page column 87, (2016/03/29)
This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
BISPHOSPHONATE COMPOUNDS FOR CHELATING RADIONUCLIDES
-
Page/Page column 42; 43, (2010/11/03)
Bisphosphonate compounds for chelating radionuclides are described which have separate bisphosphonate and metal chelating groups joined by a linker, so that the bisphosphonate groups are available to complex to hydroxyapatite in bone, while the metal chelating group binds to the radionuclide. This avoids problems in the prior art, where the bisphosphonate groups are used for both binding functions which compromises the bone-seeking activity of the bisphosphonate groups when they are used to chelate the radionuclide.